Table of Contents September 01, 2017; Volume Issue Supplement 2

  1. Lapa, Constantin

    1. CXCR4 Ligands: The Next Big Hit?
      Annemiek M.E. Walenkamp, Constantin Lapa, Ken Herrmann and Hans-Jürgen Wester
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 77S-82S; DOI: https://doi.org/10.2967/jnumed.116.186874

  2. Larson, Steven M.

    1. Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview
      Ken Herrmann, Steven M. Larson and Wolfgang A. Weber
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 1S-2S; DOI: https://doi.org/10.2967/jnumed.117.199570

  3. Lassmann, Michael

    1. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
      Uta Eberlein, Marta Cremonesi and Michael Lassmann
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 97S-103S; DOI: https://doi.org/10.2967/jnumed.116.186841

  4. Levine, Rachel

    1. Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
      Rachel Levine and Eric P. Krenning
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 3S-9S; DOI: https://doi.org/10.2967/jnumed.116.186502

  5. Lub-de Hooge, Marjolijn N.

    1. Theranostics Using Antibodies and Antibody-Related Therapeutics
      Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries
      Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 83S-90S; DOI: https://doi.org/10.2967/jnumed.116.186940
Back to top

In this issue